礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LLY 礼来

盘后交易 05-29 18:16:22 EDT

811.53

+3.67

+0.45%

盘后812.51

+0.98+0.12%

18:16 EDT

最高815.61	最低802.09	成交量237.94万
今开803.00	昨收807.86	日振幅1.67%
总市值7,716亿	流通市值7,693亿	总股本9.51亿
成交额19.27亿	换手率0.25%	流通股本9.48亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"LLY","market":"US","secType":"STK","nameCN":"礼来","latestPrice":811.53,"timestamp":1717012800000,"preClose":807.86,"halted":0,"volume":2379408,"hourTrading":{"tag":"盘后","latestPrice":812.505,"preClose":811.53,"latestTime":"18:16 EDT","volume":162102,"amount":131550603.63960001,"timestamp":1717020973520},"delay":0,"floatShares":948000000,"shares":950766100,"eps":5.8,"marketStatus":"盘后交易","marketStatusCode":4,"change":3.67,"latestTime":"05-29 18:16:22 EDT","open":803,"high":815.61,"low":802.09,"amount":1927121656.6675198,"amplitude":0.016736,"askPrice":815,"askSize":2,"bidPrice":810,"bidSize":14,"shortable":3,"etf":0,"ttmEps":5.8,"exchange":"NYSE","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1717027200000},"adr":0,"listingDate":102488400000,"adjPreClose":807.86,"adrRate":0,"dividendRate":0.005779,"preHourTrading":{"tag":"盘前","latestPrice":802.85,"preClose":807.86,"latestTime":"09:29 EDT","volume":4097,"amount":3282608.70541,"timestamp":1716989399999},"postHourTrading":{"tag":"盘后","latestPrice":812.505,"preClose":811.53,"latestTime":"18:16 EDT","volume":162102,"amount":131550603.63960001,"timestamp":1717020973520},"volumeRatio":0.888543},"requestUrl":"/m/hq/s/LLY/tweets","defaultTab":"tweets","newsList":[{"id":"2439597346","title":"美银证券发布基于三重动量股票名单：英伟达、礼来、小摩名列前茅","url":"https://stock-news.laohu8.com/highlight/detail?id=2439597346","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2439597346?lang=zh_cn&edition=full","pubTime":"2024-05-29 15:05","pubTimestamp":1716966345,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美银证券发布了基于盈利、价格和新闻情绪的“三重动量”股票名单。目前，银行、多元化金融和保险的三重动量最强，而公用事业、电信和消费类股票的三重动量最弱。美银证券指出，在美国股市中，三重动量最强的是英伟达、礼来和摩根大通。放眼全球，三重动量最强的是日本MS&AD保险、韩国半导体公司SK海力士和中国台湾芯片供应商联发科，三重动量最弱的是星巴克、施贵宝和法国奢侈品集团开云集团。","market":"us","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1127562.html","is_publish_highlight":true,"gpt_icon":1},{"id":"2438308303","title":"礼来跌0.92% 股价跌破800美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2438308303","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2438308303?lang=zh_cn&edition=full","pubTime":"2024-05-28 21:50","pubTimestamp":1716904216,"startTime":"0","endTime":"0","summary":"北京时间2024年05月28日21时50分，礼来股票出现异动，股价大幅下挫0.92%。截至发稿，该股报800.00美元/股，成交量27.1458万股，换手率0.03%，振幅0.97%。礼来股票所在的制药行业中，整体跌幅为0.77%。同时，在建设期间，预计将创造超过5000个建筑工作岗位。据悉，礼来中国区已安排了团队专门负责替尔泊肽市场。2019年信达从礼来获得玛仕度肽在中国共同开发和商业化权益，金额未公开。自进入中国市场以来，礼来先后在苏州投建了3家生产基地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240528215017aef21b4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240528215017aef21b4c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2438258153","title":"分析-随着供应量增长，减肥药预测值跃升至 1,500 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2438258153","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2438258153?lang=zh_cn&edition=full","pubTime":"2024-05-28 18:00","pubTimestamp":1716890406,"startTime":"0","endTime":"0","summary":"预计年增长率为27%，而之前的预测为13%。如果不扩大保险范围，IQVIA 认为 2028 年全球肥胖症药物支出的低端为 390 亿美元，而更有可能达到 740 亿美元。Leerink 预测，到 2032 年，年销售额将达到 1580 亿美元。这些新药在美国的上市价格超过每月 1,000 美元，它们的销售使礼来和诺和诺德跻身全球最有价值公司的行列。根据 IQVIA 的数据，超过 80 种试验性肥胖症药物已进入人体试验阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2438874363","title":"GLP-1&减肥药ETF：礼来、诺和诺德领涨，市场增长潜力巨大","url":"https://stock-news.laohu8.com/highlight/detail?id=2438874363","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2438874363?lang=zh_cn&edition=full","pubTime":"2024-05-28 06:56","pubTimestamp":1716850582,"startTime":"0","endTime":"0","summary":"快讯正文随着Roundhill Investments推出的GLP-1&减肥药ETF在纳斯达克交易所上市，市场对GLP-1药物制造商的关注度显著提升。礼来和诺和诺德作为该ETF的前两大持仓，其股价在过去一年分别上涨了90%和68%。Roundhill Investments首席执行官戴夫·马扎认为，减肥药行业仍处于初期阶段，市场增长潜力巨大。这些公司均在GLP-1和减肥药领域有所布局。分析师Edmund Ingham和Terry Chrisomalis分别看好礼来和诺和诺德的下一代减肥药物，认为这些药物可能成为市场的下一个爆点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240528065743956b2fbf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240528065743956b2fbf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2438345335","title":"金凯生科：目前与礼来的合作不涉及减肥药项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2438345335","media":"第一财经","top":-1,"share":"https://www.laohu8.com/m/news/2438345335?lang=zh_cn&edition=full","pubTime":"2024-05-27 23:03","pubTimestamp":1716822202,"startTime":"0","endTime":"0","summary":"金凯生科在互动平台表示，公司目前与礼来的合作不涉及减肥药项目。公司始终积极关注客户业务进展动态，并努力拓展推进符合自身发展的业务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240527230322af8a7bda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240527230322af8a7bda&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2438383200","title":"肥胖症药物注射剂生产商格雷斯海默在美国扩大产能","url":"https://stock-news.laohu8.com/highlight/detail?id=2438383200","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2438383200?lang=zh_cn&edition=full","pubTime":"2024-05-27 19:34","pubTimestamp":1716809657,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透5月27日 - 德国药瓶生产商Gerresheimer   周一宣布扩大其在美国的生产基地，因为该 (link)，包括GLP-1类减肥药的需求不断增长。 该公司将投资约 1.66 亿欧元(1.8024 亿美元) 建造两座大楼，在桃树市创造 400 个新的就业机会。 该基地生产自动注射器，可用于糖尿病和肥胖症治疗 (link)，如诺和诺德的  Wegovy和礼来的  Zepbound，以及其他医疗设备。(1 美元 = 0.9210 欧元)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2438276078","title":"司美格鲁肽的最强对手来了！礼来入局“减肥神药”国内市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2438276078","media":"华夏时报","top":-1,"share":"https://www.laohu8.com/m/news/2438276078?lang=zh_cn&edition=full","pubTime":"2024-05-27 13:18","pubTimestamp":1716787100,"startTime":"0","endTime":"0","summary":"本报（chinatimes.net.cn）记者杨燕 于娜 北京报道随着另一位重磅选手的入场，被冠以“减肥神药”概念股的GLP-1类市场再次风起云涌。5月21日，礼来官微发文表示，旗下替尔泊肽注射液（商品名：穆峰达）已获得国家药品监督管理局批准，用以改善成人2型糖尿病患者的血糖控制，“司美格鲁肽的最强对手来了吗？”这一话题也随之...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OWzwDPfhRjTzruh_OGBq34TaxeA82UmY_I2SatjmTfU8sAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OWzwDPfhRjTzruh_OGBq34TaxeA82UmY_I2SatjmTfU8sAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240527A047AE00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240527A047AE00","is_publish_highlight":false,"gpt_icon":0},{"id":"2438017987","title":"礼来拟再斥资53亿美元，以扩大Mounjaro和Zepbound产量","url":"https://stock-news.laohu8.com/highlight/detail?id=2438017987","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2438017987?lang=zh_cn&edition=full","pubTime":"2024-05-27 07:59","pubTimestamp":1716767954,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼来将在此前宣布的37亿美元基础上再斥资53亿美元，用于提高位于印第安纳州黎巴嫩地区的活性药物成分生产基地的产能。该制药商表示，这笔投资将提高2型糖尿病药物Mounjaro和减肥药物Zepbound的活性成分tirzepatide产量，此外还将提高管线药物的产量。礼来指出，新投资将为工程师、科学家、操作人员和实验室技术人员增加200个全职工作岗位。据了解，礼来位于该地区的生产基地于2023年破土动工。","market":"sh","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1126134.html","is_publish_highlight":true,"gpt_icon":0},{"id":"1149122217","title":"礼来150年历史上最大投资！加码“减肥药”，53亿美元扩产能","url":"https://stock-news.laohu8.com/highlight/detail?id=1149122217","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/1149122217?lang=zh_cn&edition=full","pubTime":"2024-05-25 08:46","pubTimestamp":1716597993,"startTime":"0","endTime":"0","summary":"最新消息指出，礼来公司计划斥资53亿美元，来扩建其位于印第安纳州的工厂，提升其减肥和糖尿病注射剂中关键成分“替尔泊肽”的产量。这是该公司近150年历史上最大的一笔投资。这是该公司近150年历史上最大的一笔投资，旨在满足其热销产品——GLP-1减肥药Zepbound和GLP-1糖尿病治疗药Mounjaro日益增长的市场需求。市场分析师预测，到2030年，减肥药市场的规模可能高达800亿美元。这表明礼来公司的投资不仅扩大了生产规模，还极大地推动了地区经济的发展。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":{"source":"wallstreetcn_api","url":"https://wallstreetcn.com/articles/3715726","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3715726","is_publish_highlight":true,"gpt_icon":1},{"id":"2438721016","title":"90亿美元！礼来投资扩大替尔泊肽产能","url":"https://stock-news.laohu8.com/highlight/detail?id=2438721016","media":"医药魔方","top":-1,"share":"https://www.laohu8.com/m/news/2438721016?lang=zh_cn&edition=full","pubTime":"2024-05-25 08:36","pubTimestamp":1716597401,"startTime":"0","endTime":"0","summary":"此次扩建将提高礼来生产替尔泊肽即Zepbound注射液和Mounjaro注射液活性药物成分的能力，从而使更多患有肥胖症和2型糖尿病等慢性疾病患者从中获益。替尔泊肽自问世以来，销售额便一路狂飙。事实上，在替尔泊肽研究成果的推动下，礼来从2020年便开始大幅扩大生产规模。自2020年以来，礼来已投入160多亿美元在美国和欧洲开发新的生产基地。这些生产投资总额超过180亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240525085857955bbb35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240525085857955bbb35&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2438902590","title":"隔夜美股全复盘(5.25)| 三大股指集体收涨，特斯拉涨超3%，在经历了数周的裁员之后，首次发布了十多个自动驾驶和人工智能职位","url":"https://stock-news.laohu8.com/highlight/detail?id=2438902590","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2438902590?lang=zh_cn&edition=full","pubTime":"2024-05-25 07:28","pubTimestamp":1716593308,"startTime":"0","endTime":"0","summary":"三大股指集体收涨，特斯拉涨超3%，在经历了数周的裁员之后，首次发布了十多个自动驾驶和人工智能职位","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/754541","is_publish_highlight":false,"gpt_icon":0},{"id":"2437037207","title":"礼来公司将花费53亿美元生产更多MounjaroZepbound-华尔街日报","url":"https://stock-news.laohu8.com/highlight/detail?id=2437037207","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2437037207?lang=zh_cn&edition=full","pubTime":"2024-05-24 21:26","pubTimestamp":1716557174,"startTime":"0","endTime":"0","summary":"礼来公司将花费53亿美元生产更多MounjaroZepbound-华尔街日报","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052421261895593a7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052421261895593a7a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2437272715","title":"英伟达收涨9.32%市值单日增加2180亿美元报1037.99美元（在业绩报告发布日收跌0.46%的情况下）时隔一个交易日再创收盘历史新高收盘市值2.55万亿美元。Meta则收跌0.43%微软跌0.82%亚马逊跌1.14%谷歌A跌1.6%苹果跌2.11%特斯拉跌3.54%。此外AMD收跌3.08%伯克希尔哈撒韦B类股跌1.96%台积电ADR则涨0.6%礼来制药涨0.69%——也时隔一天再创收盘历史新高市值将近7700亿美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2437272715","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2437272715?lang=zh_cn&edition=full","pubTime":"2024-05-24 04:35","pubTimestamp":1716496543,"startTime":"0","endTime":"0","summary":"英伟达收涨9.32%市值单日增加2180亿美元报1037.99美元（在业绩报告发布日收跌0.46%的情况下）时隔一个交易日再创收盘历史新高收盘市值2.55万亿美元。Meta则收跌0.43%微软跌0.82%亚马逊跌1.14%谷歌A跌1.6%苹果跌2.11%特斯拉跌3.54%。此外AMD收跌3.08%伯克希尔哈撒韦B类股跌1.96%台积电ADR则涨0.6%礼来制药涨0.69%——也时隔一天再创收盘历史新高市值将近7700亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240524043547955517e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240524043547955517e9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2437754926","title":"礼来：杰富瑞将目标价从915美元上调至925美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2437754926","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2437754926?lang=zh_cn&edition=full","pubTime":"2024-05-23 20:45","pubTimestamp":1716468339,"startTime":"0","endTime":"0","summary":"礼来：杰富瑞将目标价从915美元上调至925美元","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405232045429edd395c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405232045429edd395c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2437783006","title":"五洲医疗(301234.SZ)：目前尚未跟礼来的替尔泊肽产品合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2437783006","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2437783006?lang=zh_cn&edition=full","pubTime":"2024-05-23 15:25","pubTimestamp":1716449115,"startTime":"0","endTime":"0","summary":"格隆汇5月23日丨五洲医疗(301234.SZ)在投资者互动平台表示，公司主营一次性使用无菌输注类医疗器械研发、制造和销售，主要产品包括注射器、输液输血器、医用穿刺针，以及其他诊断和临床护理产品。公司目前尚未跟礼来的替尔泊肽（Tirzepatide）产品合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052315252895524e42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052315252895524e42&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2437039992","title":"更新 1-德国 Gerresheimer 公司将以 8.66 亿美元收购 Blitz LuxCo 公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2437039992","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2437039992?lang=zh_cn&edition=full","pubTime":"2024-05-23 12:58","pubTimestamp":1716440339,"startTime":"0","endTime":"0","summary":"     路透5月23日 - 德国包装和医疗设备制造商Gerresheimer   周四表示，它签署了收购Bormioli Pharma集团控股公司Blitz LuxCo Sarl的收购协议，企业价值为8亿欧元。这家医疗设备制造商表示，这项交易将由联合信贷银行、德国商业银行和LBBW组成的银行财团出资，预计将于2024年第四季度完成。该公司在声明中表示，整合后将创建一个新的 \"模制玻璃 \"业务部门。Gerresheimer 公司生产的注射器  用于诺和诺德公司的   Wegovy 和礼来公司的   Zepbound 的注射。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2437264792","title":"港股概念追踪 | 减肥神药“升级版”来了！礼来替尔泊肽国内获批 产业迎来成果突破爆发期(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2437264792","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2437264792?lang=zh_cn&edition=full","pubTime":"2024-05-23 07:56","pubTimestamp":1716422192,"startTime":"0","endTime":"0","summary":"据了解，替尔泊肽是一款每周注射一次的GIPR和GLP-1R激动剂。相关研究数据表明表明，穆峰达5mg、10mg受试者体重平均降低7.8kg、10.3kg，司美格鲁肽1mg组平均降低6.2kg。同时，替尔泊肽在定价上也低于司美格鲁肽，成为了肥胖及超重人群药物治疗的优选。国内已获批的GLP-1产品中，仁会生物的贝那鲁肽和华东医药的利拉鲁肽生物类似物除了糖尿病治疗，亦获批用于肥胖的治疗。随着诺和诺德、礼来的GLP-1靶点减重药研发趋势，减重药产业迎来成果突破爆发期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1124876.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437742225","title":"隔夜美股全复盘(5.23)| 英伟达净利暴增628%，宣布进行1拆10，营收及指引均超预期，盘后股价突破1000","url":"https://stock-news.laohu8.com/highlight/detail?id=2437742225","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2437742225?lang=zh_cn&edition=full","pubTime":"2024-05-23 07:39","pubTimestamp":1716421147,"startTime":"0","endTime":"0","summary":"英伟达净利暴增628%，宣布进行1拆10，营收及指引均超预期，盘后股价突破1000","market":"us","thumbnail":"https://static.tigerbbs.com/f99f24db6c49bc285a0fe73ae0252f23","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f99f24db6c49bc285a0fe73ae0252f23"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/748839","is_publish_highlight":false,"gpt_icon":1},{"id":"2437225047","title":"减肥药混战时代，开启?","url":"https://stock-news.laohu8.com/highlight/detail?id=2437225047","media":"中国新闻网","top":-1,"share":"https://www.laohu8.com/m/news/2437225047?lang=zh_cn&edition=full","pubTime":"2024-05-23 07:30","pubTimestamp":1716420605,"startTime":"0","endTime":"0","summary":"此前，司美格鲁肽的针剂和口服药在国内已获批用于糖尿病适应症。其活性成分与热门品牌减肥药Ozempic和Wegovy相同，价格约为199美元。按照司美格鲁肽注射用减肥版本Wegovy在美国市场的定价1350美元计算，Hims & Hers Health的配方制剂注射版价格将降低85%。就在5月初，诺和诺德方面曾表示，由于销量巨大加上竞争激烈，诺和诺德计划下调其减肥药Wegovy在美国的售价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405230745218788b6c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405230745218788b6c8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2437403261","title":"“减肥神药”大消息，全球市值第一药企礼来创新高！产业渗透率提升空间巨大，这些A股公司增长潜力足","url":"https://stock-news.laohu8.com/highlight/detail?id=2437403261","media":"数据宝","top":-1,"share":"https://www.laohu8.com/m/news/2437403261?lang=zh_cn&edition=full","pubTime":"2024-05-22 19:50","pubTimestamp":1716378651,"startTime":"0","endTime":"0","summary":"相关研究数据表明表明，穆峰达5mg、10mg受试者体重平均降低7.8kg、10.3kg，司美格鲁肽1mg组平均降低6.2kg。对于此次该药物的获批，礼来方面表示，替尔泊肽注射液的获批代表着糖尿病研发领域的突破性进步。减肥药市场存在较大增长空间目前，由于GLP-1价格高、患者认知程度不高等原因，中国GLP-1RA药物在患者中的渗透率较低。这也意味着，未来药品渗透空间较大。多只减肥药概念股未来前景获机构看好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405221953238787638a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405221953238787638a&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lilly.com","stockEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":0.1014},{"period":"3month","weight":0.0663},{"period":"6month","weight":0.3668},{"period":"1year","weight":0.8973},{"period":"ytd","weight":0.3859}],"compareEarnings":[{"period":"1week","weight":-0.0029},{"period":"1month","weight":0.0424},{"period":"3month","weight":0.0465},{"period":"6month","weight":0.1608},{"period":"1year","weight":0.2614},{"period":"ytd","weight":0.1147}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"礼来公司于1901年在印第安纳州注册成立，其前身是1876年由伊利·礼来上校在印第安纳州印第安纳波利斯创立的药品生产企业。公司发现，开发，制造和销售重要医药产品。公司的宗旨是将“关爱”与“发现”结合起来，为世界各地的人们创造更美好的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.011498},{"month":2,"riseRate":0.5,"avgChangeRate":-0.002909},{"month":3,"riseRate":0.613636,"avgChangeRate":0.015389},{"month":4,"riseRate":0.555556,"avgChangeRate":0.018718},{"month":5,"riseRate":0.422222,"avgChangeRate":0.014561},{"month":6,"riseRate":0.590909,"avgChangeRate":0.021126},{"month":7,"riseRate":0.568182,"avgChangeRate":0.002184},{"month":8,"riseRate":0.409091,"avgChangeRate":0.00001},{"month":9,"riseRate":0.454545,"avgChangeRate":0.003204},{"month":10,"riseRate":0.590909,"avgChangeRate":0.014439},{"month":11,"riseRate":0.75,"avgChangeRate":0.027866},{"month":12,"riseRate":0.590909,"avgChangeRate":0.031834}],"exchange":"NYSE","name":"礼来","nameEN":"Eli Lilly"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"礼来,LLY,礼来股票,礼来股票老虎,礼来股票老虎国际,礼来行情,礼来股票行情,礼来股价,礼来股市,礼来股票价格,礼来股票交易,礼来股票购买,礼来股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}